Skip to main content

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.

Publication ,  Journal Article
Hoenigl, M; Seidel, D; Carvalho, A; Rudramurthy, SM; Arastehfar, A; Gangneux, J-P; Nasir, N; Bonifaz, A; Araiza, J; Klimko, N; Serris, A ...
Published in: Lancet Microbe
July 2022

Reports of COVID-19-associated mucormycosis have been increasing in frequency since early 2021, particularly among patients with uncontrolled diabetes. Patients with diabetes and hyperglycaemia often have an inflammatory state that could be potentiated by the activation of antiviral immunity to SARS-CoV2, which might favour secondary infections. In this Review, we analysed 80 published and unpublished cases of COVID-19-associated mucormycosis. Uncontrolled diabetes, as well as systemic corticosteroid treatment, were present in most patients with COVID-19-associated mucormycosis, and rhino-orbital cerebral mucormycosis was the most frequent disease. Mortality was high at 49%, which was particularly due to patients with pulmonary or disseminated mucormycosis or cerebral involvement. Furthermore, a substantial proportion of patients who survived had life-changing morbidities (eg, loss of vision in 46% of survivors). Our Review indicates that COVID-19-associated mucormycosis is associated with high morbidity and mortality. Diagnosis of pulmonary mucormycosis is particularly challenging, and might be frequently missed in India.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet Microbe

DOI

EISSN

2666-5247

Publication Date

July 2022

Volume

3

Issue

7

Start / End Page

e543 / e552

Location

England

Related Subject Headings

  • SARS-CoV-2
  • Risk Factors
  • RNA, Viral
  • Mucormycosis
  • Humans
  • Diabetes Mellitus
  • COVID-19
  • 3207 Medical microbiology
  • 3204 Immunology
  • 3107 Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hoenigl, M., Seidel, D., Carvalho, A., Rudramurthy, S. M., Arastehfar, A., Gangneux, J.-P., … ECMM and ISHAM collaborators, . (2022). The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, 3(7), e543–e552. https://doi.org/10.1016/S2666-5247(21)00237-8
Hoenigl, Martin, Danila Seidel, Agostinho Carvalho, Shivaprakash M. Rudramurthy, Amir Arastehfar, Jean-Pierre Gangneux, Nosheen Nasir, et al. “The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.Lancet Microbe 3, no. 7 (July 2022): e543–52. https://doi.org/10.1016/S2666-5247(21)00237-8.
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux J-P, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jul;3(7):e543–52.
Hoenigl, Martin, et al. “The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.Lancet Microbe, vol. 3, no. 7, July 2022, pp. e543–52. Pubmed, doi:10.1016/S2666-5247(21)00237-8.
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux J-P, Nasir N, Bonifaz A, Araiza J, Klimko N, Serris A, Lagrou K, Meis JF, Cornely OA, Perfect JR, White PL, Chakrabarti A, ECMM and ISHAM collaborators. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jul;3(7):e543–e552.

Published In

Lancet Microbe

DOI

EISSN

2666-5247

Publication Date

July 2022

Volume

3

Issue

7

Start / End Page

e543 / e552

Location

England

Related Subject Headings

  • SARS-CoV-2
  • Risk Factors
  • RNA, Viral
  • Mucormycosis
  • Humans
  • Diabetes Mellitus
  • COVID-19
  • 3207 Medical microbiology
  • 3204 Immunology
  • 3107 Microbiology